SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JOSEPH VON MEISTER who wrote (217)9/20/1997 10:16:00 PM
From: Miljenko Zuanic   of 1826
 
David:

Thanks for update. Its make sense but my shadow of the concern didn't completely disappear.

In one hand, if they want more patients enrolled why not expand current trials with slightly change protocol. It will save time. Data still can be useful for PII designee. Generally investors do not like repeat trial if there are no strong reasons for it.

On other hand, if they observed some unexpected drug property (good or bad) it will be wised to repeat PI trials to clear this properly before going to PII. Also, for some indication PII can start early (after interim data on second PI).

Or, MOGN is going in collaboration with MGI-144 (based on current trials data) where partner will conduct large PI trials in broad cancer indication to determine additional drug safety and toxicity profile and to obtain initial efficiency data for several indication?

MGI-144 cytotoxicity to *regular* cells is something which have to be addressed with respects. This will determine drug future: will it be another toxic neoplastic agent or it will be new much safer and effective anti-cancer therapy.

Hope, MOGN will inform its shareholders on MGI-144 clinical progress in quaternary report.


Joseph:

>>What I think the autor is really saying...<

Correct. I am not connecting any angiogenic side effects to MGI-144. Problem for MGI-144 may be cytotoxicity to normal cells.
Anti-angiogenesis do have side effects problems , IMO, and it may be limiting factors for this approach to cancer therapy. It is to early to define any projection. By this, improved chemotherapy my have good future. Hope this will be case for MGI-144.

I agree with Richard that selective tissue/tumor-specific targeting with effective, but toxic, agents make sense for MOGN.

For the MOGN followers info., Friday I added another small shares portion to my MOGN holding. At this point downside risk is equal to zero or less, and upward potential can change significantly at no time.

mz
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News